The Centers for Disease Control and Prevention on Monday said it had officially recommended updated COVID vaccines, creating a new system to get a shot that’s slightly more complicated than in previous years.
The high court granted a joint request from Rokita and the Indiana Supreme Court Disciplinary Commission to dismiss the case as moot, saying the two sides had resolved their dispute.
Lawmakers also expressed appetite for ditching the Professional Licensing Agency, an umbrella body overseeing 33 profession-specific licensing entities—like the Board of Pharmacy.
Indiana’s hospital systems could face hundreds of millions of dollars in annual Medicaid reimbursement cuts if the rates they charge to employer-provided insurance plans are higher than thresholds set by Gov. Mike Braun’s administration.
The test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but is designed to rule out the presence of the disease’s pathology early on, or indicate further diagnostics are needed.
Kevin Calvert, 57, was charged with 43 counts of Medicaid fraud and an additional count of theft following an investigation by the attorney general’s Medicaid Fraud Control Unit.
Advocates for transgender Hoosiers spoke in opposition to an Indiana Bureau of Motor Vehicles regulation revision to prohibit gender marker changes that have been allowed since 2009.
The strategic consulting agreement with the Fort Wayne-based hospital system comes as the Hamilton County-owned Riverview is recovering from consecutive years of operating losses.
In total, 29 executives—including six CEOs of the Year—will be honored at a 5 p.m. event on Dec. 2 at the Indiana Roof Ballroom. Tickets are still available.
Dr. Michael Meneghini waited out a two-year noncompete clause after leaving Indiana University Health before opening the $35 million Indiana Orthopedic Institute early this year.
As GLP-1 drugs for weight loss and diabetes drugs such as Zepbound and Mounjaro generate billions in sales, researchers at Eli Lilly and Co. and other pharma companies are exploring their potential for other purposes.
